The potent and selective anti-tumor activity of our 8H8_SDIE in preclinical settings underscores its potential as a promising therapeutic option and could provide substantial benefit to patients with NSCLC and other CD276-positive malignancies, potentially overcoming the limitations of PD-L1 dependent strategies. The gene discussed is CD276; the disease is neoplasm.